Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ICO Information Centre on HPV and Cancer Jordan Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19) I. Key data on HPV and HPV-related cancers 1.6 0.2 Normal cytology(3) Low−grade lesions(4) HPV−type Female 0.2 HPV−type Male No data available 1st* 2nd* 3rd* 4th* 5th* 6th* 7th* 8th* 9th* 10th* No data available HPV−type Cervical cancer Anal cancer Vulva cancer Vaginal cancer Penile cancer Pharynx (excluding nasopharynx) 1st* 2nd* 3rd* 4th* 5th* 6th* 7th* 8th* 9th* 10th* 1st* 2nd* 3rd* 4th* 5th* 6th* 7th* 8th* 9th* 10th* No data available HPV−type Crude incidence rates of HPV-related High−grade lesions(5) Table 1. cancers Figure 1. Comparison of the ten most frequent HPV oncogenic types in Jordan among women with and without cervical lesions Cervical Cancer(1, 2) Jordan has a population of 2.38 millions women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 50 women are diagnosed with cervical cancer and 19 die from the disease. Cervical cancer ranks as the 15th most frequent cancer among women in Jordan and the 10th most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the HPV burden in the general population of Jordan. However, in Western Asia, the region Jordan belongs to, about 2.3% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 72.4% of invasive cervical cancers are attributed to HPVs 16 or 18. 16 18 56 39 45 33 59 35 31 58 68.3 24.4 9.8 9.8 7.3 4.9 2.4 2.4 2.4 2.4 0 10 20 30 40 50 60 Prevalence (%) Table 2. Burden of cervical cancer ∗No data available. No more types than shown were tested or were positive. Incidence Mortality Annual number of new cases/deaths Crude rate Age-standarized rate Cumulative risk 0-74 years (%) Ranking of cervical cancer (all years) Ranking of cervical cancer (15-44 years) 50 1.6 2.4 0.2 15th 10th 19 0.6 1.0 0.1 17th 13th Table 3. Burden of cervical HPV infection Jordan No. Tested HPV prevalence in women with normal cytology HPV 16/18 prevalence: Normal cytology Low-grade cervical lesions High-grade cervical lesions Cervical cancer 41 % (95% CI) ----92.7 (80.6-97.5) For data sources and further data on HPV infection in cancer sites other than the cervix, please refer to the specific country full report. 70 ICO Information Centre on HPV and Cancer Jordan Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19) II. Complementary data on cervical cancer prevention Table 4. Factors contributing to cervical cancer (cofactors) Table 7. Cervical screening practices and recommendations Smoking prevalence (%), women Total fertility rate (live births per women) 3.8 Cervical cancer screening coverage, % (age and screening interval, reference) Hormonal contraception use (%) (pill, injectable or implant), among women 9.3 Screening ages (years) 25-35 Screening interval (years) or frequency of screens - 10.2 HIV prevalence (%), adults (15-49 years) - Table 5. Sexual behaviour 18.8% (All women aged 15-49 ever screened, DHS 2012 Jordan) Figure 2. Estimated coverage of cervical cancer screening in Jordan, by age and study MEN Percentage of 15-year-old who have had sexual intercourse - Range of median age at first sexual intercourse - − All women ever screened − All women screened every 0 in 2012 − in 2007 − 100 100 80 80 60 60 Percentage of 15-year-old who have had sexual intercourse 0.5 Range of median age at first sexual intercourse - Table 6. HPV vaccine introduction HPV vaccination programme Date of HPV vaccination immunization programme start No Program routine HPV vaccination target age for routine immunization - Estimated cervical cancer screening coverage (%) WOMEN 40 40 26.8 25.7 19.7 20 20 11.0 - 9.2 2.8 2.7 0 0 15−19 20−34 35−49 0 0 0 0 Full course HPV vaccination coverage for routine immunization: % (calendar year) - Contact information: ICO HPV Information Centre Institut Català d’Oncologia Avda. Gran Via de l’Hospitalet, 199-203 08908 L’Hospitalet de Llobregat (Barcelona, Spain) e-mail: [email protected] internet adress: www.hpvcentre.net For data sources and further data on HPV infection in cancer sites other than the cervix, please refer to the specific country full report.